Here is a shot study for it to help people stop smoking.
https://www.ncbi.nlm.nih.gov/pubmed/23685330
Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. - PubMed -...
Addict Behav. 2013 Sep;38(9):2433-6. doi: 10.1016/j.addbeh.2013.03.011. Epub 2013 Apr 1. Randomized Controlled Trial; Research Support, Non-U.S. Gov't
https://zynerba.com/zynerba-pharmaceuticals-announces-results-phase-2-stop-trial-support-continued-development-zyn002-osteoarthritis/
Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued...
Zynerba to host conference call and webcast today, August 14 at 8:30 am ET Devon, PA,Aug. 14, 2017 –Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today reported top line results from its Phase 2 STOP (SyntheticTransdermal Cannabidiol for Treatment of KneePain due to…
CBD has been shown to interact with the body’s endocannabinoid system, a network in the brain that seems to play a role in social behavior, circadian rhythm, and reward processing—all of which can be atypical in people with autism. For that reason, researchers are excited about a study that’s currently underway at the University of California San Diego about CBD’s potential as an autism therapy.
https://www.cmcr.ucsd.edu/index.php/?option=com_content&view=article&id=123/
This clinical trial will examine if and how cannabidiol (CBD), a chemical found in the cannabis plant, provides therapeutic benefit to children with severe autism spectrum disorder (ASD). The trial, scheduled to launch in approximately one year, is funded by a grant from the Ray and Tye Noorda Foundation in partnership with and based on recommendations from the Wholistic Research and Education Foundation.